Followers | 267 |
Posts | 35473 |
Boards Moderated | 4 |
Alias Born | 01/24/2013 |

Wednesday, July 17, 2024 10:55:45 AM
As for what I'm seeing on TorS, there is no Bid, nor an Ask.
My take is, nobody that is qualified is holding shares at this time, but also, nobody that is qualified wants any.
Evidently, that wasn't true early on, because it is showing a volume of 320,588. That number has not changed in the last 30 mins.
JMO but, his stunt to avoid the consequences of the rules for reporting, has cost him in terms of NO BID. Anyone that is able to Buy, would see that Form 15-12G and say "NO Thank You".
A sure sign that the debate has been won:
When the response is an attack against the other person.
Recent YCRM News
- Frequency Holdings YCRM Announces Addition of David Meltzer to Board of Directors, Joining Kevin Harrington to Accelerate Growth and Uplisting Strategy • InvestorsHub NewsWire • 06/30/2025 02:11:29 PM
- Yuengling's Ice Cream Corporation (OTC: YCRM), Doing Business as ReachOut, Files 2024 10-K With Profitability, Growth, and Corporate Transformation in Focus • InvestorsHub NewsWire • 04/16/2025 03:07:44 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/15/2025 09:00:32 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2025 08:17:01 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 03/12/2025 12:26:14 PM
- YCRM ReachOut Technology Returns to Trading: CEO Rick Jordan Lays Out Blockchain CyberSecurity Strategy and Industry-First AI MSP Partnership In Shareholder Letter • InvestorsHub NewsWire • 02/18/2025 04:20:56 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/31/2025 08:05:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/19/2024 10:27:12 PM
- Form 10-KT - Transition reports [Rule 13a-10 or 15d-10] • Edgar (US Regulatory) • 09/11/2024 07:17:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 07:38:17 PM
FEATURED Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • CLDI • Jul 7, 2025 9:00 AM
VAYK Discloses More Insider Buying Approaching 15 Million • VAYK • Jul 2, 2025 10:37 AM